Fulcrum Asset Management LLP purchased a new position in shares of Medline (NASDAQ:MDLN – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,728 shares of the company’s stock, valued at approximately $445,000.
A number of other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its position in shares of Medline by 30,255.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after acquiring an additional 2,691,529 shares in the last quarter. Pictet Asset Management Holding SA grew its position in Medline by 21.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 215,114 shares of the company’s stock worth $7,464,000 after acquiring an additional 37,928 shares during the last quarter. Covestor Ltd grew its holdings in shares of Medline by 31.8% during the third quarter. Covestor Ltd now owns 1,953 shares of the company’s stock worth $68,000 after purchasing an additional 471 shares during the last quarter. Rakuten Investment Management Inc. increased its position in Medline by 13.6% in the 3rd quarter. Rakuten Investment Management Inc. now owns 24,482 shares of the company’s stock valued at $856,000 after acquiring an additional 2,925 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Medline in the third quarter valued at $87,000.
Medline Stock Performance
Shares of MDLN opened at $39.47 on Monday. The firm has a market cap of $51.92 billion and a PE ratio of 89.71. Medline has a 1 year low of $31.37 and a 1 year high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51. The stock’s fifty day moving average price is $35.28 and its two-hundred day moving average price is $39.37.
Medline (NASDAQ:MDLN – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion during the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. On average, equities research analysts forecast that Medline will post 1.58 EPS for the current year.
Insider Transactions at Medline
In other Medline news, major shareholder Private Ltd Gic sold 2,088,987 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the transaction, the insider owned 16,453,806 shares in the company, valued at $576,705,900.30. This trade represents a 11.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 6,348,676 shares of company stock worth $224,525,137. Corporate insiders own 0.81% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have weighed in on MDLN. Royal Bank Of Canada decreased their target price on shares of Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Citigroup boosted their target price on Medline from $45.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. JPMorgan Chase & Co. decreased their price target on shares of Medline from $53.00 to $46.00 and set an “overweight” rating for the company in a research note on Wednesday, August 12th. Wall Street Zen raised Medline from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Barclays lowered their target price on shares of Medline from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 9th. Twenty-three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.08.
Read Our Latest Stock Analysis on MDLN
About Medline
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Featured Articles
- Five stocks we like better than Medline
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
